Market Research Logo

Insomnia - Pipeline Review, H1 2015

Insomnia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Insomnia - Pipeline Review, H1 2015’, provides an overview of the Insomnia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Insomnia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Insomnia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Insomnia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Insomnia Overview
Therapeutics Development
Pipeline Products for Insomnia - Overview
Pipeline Products for Insomnia - Comparative Analysis
Insomnia - Therapeutics under Development by Companies
Insomnia - Therapeutics under Investigation by Universities/Institutes
Insomnia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Insomnia - Products under Development by Companies
Insomnia - Products under Investigation by Universities/Institutes
Insomnia - Companies Involved in Therapeutics Development
Actelion Ltd
Alexza Pharmaceuticals, Inc.
Eisai Co., Ltd.
Evotec AG
Grupo Ferrer Internacional, S.A.
Heptares Therapeutics Ltd.
Intec Pharma ltd.
Intra-Cellular Therapies, Inc.
Johnson & Johnson
Merck & Co., Inc.
Minerva Neurosciences, Inc.
Neurim Pharmaceuticals Ltd
Novartis AG
Reviva Pharmaceuticals Inc.
Rottapharm SpA
Shionogi & Co., Ltd.
Somnus Therapeutics, Inc.
Takeda Pharmaceutical Company Limited
Insomnia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACT-462206 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-5542 Series - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EVT-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42847922 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LASSBio-785 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LASSBio-786 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lemborexant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lorediplon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIN-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-8133 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramelteon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP-15000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-117957 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit OX2R for Insomnia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
UCM-765 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zaleplon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zaleplon DR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zaleplon GR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
zolpidem tartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Insomnia - Recent Pipeline Updates
Insomnia - Dormant Projects
Insomnia - Discontinued Products
Insomnia - Product Development Milestones
Featured News & Press Releases
Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
Dec 10, 2014: Eisai Demonstrates Efficacy Of Investigational Dual Orexin Receptor Antagonist E2006 In Sleep Initiation And Maintenance
Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial
Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia
Feb 09, 2012: Ferrer Announces Positive Results From Phase I Clinical Trials Of Lorediplon In Insomnia
Dec 14, 2011: McGill University Health Centre Researchers Discover Potential Insomnia Drug
Oct 07, 2011: Takeda Discontinues Development Of Ramelteon In Europe For Treatment Of Insomnia
Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11
Jun 15, 2011: Somnus's Phase II Study Of SKP-1041 For Sleep Maintenance Insomnia Shows Significant Reduction Of Mid-Night Awakenings without Next-Day Cognitive Impairment
Jun 01, 2011: Somnus Therapeutics Completes Successful Phase II Study Of SKP-1041 For Sleep Maintenance Insomnia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Insomnia, H1 2015
Number of Products under Development for Insomnia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Insomnia - Pipeline by Actelion Ltd, H1 2015
Insomnia - Pipeline by Alexza Pharmaceuticals, Inc., H1 2015
Insomnia - Pipeline by Eisai Co., Ltd., H1 2015
Insomnia - Pipeline by Evotec AG, H1 2015
Insomnia - Pipeline by Grupo Ferrer Internacional, S.A., H1 2015
Insomnia - Pipeline by Heptares Therapeutics Ltd., H1 2015
Insomnia - Pipeline by Intec Pharma ltd., H1 2015
Insomnia - Pipeline by Intra-Cellular Therapies, Inc., H1 2015
Insomnia - Pipeline by Johnson & Johnson, H1 2015
Insomnia - Pipeline by Merck & Co., Inc., H1 2015
Insomnia - Pipeline by Minerva Neurosciences, Inc., H1 2015
Insomnia - Pipeline by Neurim Pharmaceuticals Ltd, H1 2015
Insomnia - Pipeline by Novartis AG, H1 2015
Insomnia - Pipeline by Reviva Pharmaceuticals Inc., H1 2015
Insomnia - Pipeline by Rottapharm SpA, H1 2015
Insomnia - Pipeline by Shionogi & Co., Ltd., H1 2015
Insomnia - Pipeline by Somnus Therapeutics, Inc., H1 2015
Insomnia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Insomnia Therapeutics - Recent Pipeline Updates, H1 2015
Insomnia - Dormant Projects, H1 2015
Insomnia - Dormant Projects (Contd..1), H1 2015
Insomnia - Dormant Projects (Contd..2), H1 2015
Insomnia - Discontinued Products, H1 2015
Insomnia - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Insomnia, H1 2015
Number of Products under Development for Insomnia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report